Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment

Show full item record



Permalink

http://hdl.handle.net/10138/328418

Citation

Peuranpää , P , Hautamaki , H , Halttunen-Nieminen , M , Hyden-Granskog , C & Tiitinen , A 2020 , ' Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment ' , Human Reproduction , vol. 35 , no. 3 , pp. 504-515 . https://doi.org/10.1093/humrep/deaa008

Title: Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment
Author: Peuranpää, P.; Hautamaki, H.; Halttunen-Nieminen, M.; Hyden-Granskog, C.; Tiitinen, A.
Contributor organization: Department of Obstetrics and Gynecology
HUS Gynecology and Obstetrics
University of Helsinki
HUS Helsinki and Uusimaa Hospital District
Hyvinkää Hospital Area
Helsinki University Hospital Area
Teachers' Academy
University Management
Clinicum
Date: 2020-03
Language: eng
Number of pages: 12
Belongs to series: Human Reproduction
ISSN: 0268-1161
DOI: https://doi.org/10.1093/humrep/deaa008
URI: http://hdl.handle.net/10138/328418
Abstract: STUDY QUESTION: Is a low ( SUMMARY ANSWER: A low or moderately low serum AMH level does not associate with miscarriage, non-visualized pregnancy loss or overall early pregnancy loss rate in the IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Low AMH predicts poor ovarian response and small oocyte yield in IVF/ICSI treatment, but its value in the evaluation of live birth rate (LBR) is modest Little is known about the risk of early pregnancy loss in ART among women with low AMH. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study on 1383 women undergoing their first oocyte retrieval for IVF/ICSI in Helsinki University Hospital in Helsinki, Finland, between 2012 and 2016, with all associated fresh (n = 1315) and frozen-thawed (n = 1418) ET cycles finished by August 2018. AMH was measured within 12 months before the IVF/ICSI stimulation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of all the women, 235 (17.0%) had low (= 2.0 mu g/L) AMH. The primary outcomes were miscarriage, non-visualized pregnancy loss and early pregnancy loss (miscarriage and non-visualized pregnancy loss combined) after fresh or frozen-thawed ET. The impact of AMH on these outcomes was calculated in three populations: among all women who became pregnant, among women with AMH MAIN RESULTS AND THE ROLE OF CHANCE: Of 1123 pregnancies, 285 (25.4%) ended in non-visualized pregnancy loss and 143 (12.7%) in miscarriage. The LBR was 24.6% per ET (673/2733). Low or moderately low AMH, compared with normal AMH, did not associate with miscarriage or non-visualized pregnancy loss in analyses among all women who became pregnant (adjusted relative risk (RR) for miscarriage vs live birth, 0.70 and 95% CI 0.42-1.17 in low AMH and adjusted RR, 1.00 and 95% CI, 0.68-1.49 in moderately low AMH; adjusted RR for non-visualized pregnancy loss vs live birth, 0.90 and 95% CI, 0.65-1.23 in low AMH and adjusted RR, 1.09 and 95% CI 0.85-1.41 in moderately low AMH), nor did low or moderately low AMH associate with the overall early pregnancy loss rate (adjusted RR for early pregnancy loss vs live birth, 0.86 and 95% CI, 0.68-1.10 in low AMH and adjusted RR, 1.01 and 95% CI, 0.86-1.27 in moderately low AMH). Results remained similar after restricting the analysis to women with AMH LIMITATIONS, REASONS FOR CAUTION: The number of miscarriages in women with low AMH was moderately small, limiting the power of the study. The real-world clinical setting of the study restricted the ability to control for all factors causing selection bias. WIDER IMPLICATIONS OF THE FINDINGS: The cLBR was higher among women with normal AMH than among women with low or moderately low AMH in their first IVF/ICSI treatment because these women had more oocytes and embryos. Women with low or moderately low AMH did not have an increased risk for early pregnancy loss. This information is reassuring for couples and useful in counseling. These results are also valuable when assessing the overall effectiveness of IVF/ICSI treatment.
Subject: anti-mullerian hormone
early pregnancy loss
miscarriage
ovarian reserve
IVF/ICSI
ASSISTED REPRODUCTIVE TECHNOLOGY
OVARIAN RESERVE
ANTIMULLERIAN HORMONE
LIVE BIRTH
MISCARRIAGE
RATES
WOMEN
IVF
3123 Gynaecology and paediatrics
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Low_anti_M_llerian_hormone_level.pdf 1.407Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record